# Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

> **NCT02207530** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 112 (actual)

## Conditions studied

- Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **DRUG:** MEDI4736

## Key facts

- **NCT ID:** NCT02207530
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-23
- **Primary completion:** 2016-09-26
- **Final completion:** 2020-07-06
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2020-09-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02207530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02207530, "Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02207530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*